Quantcast

Latest schizophrenia Stories

2014-10-30 12:30:01

Surveyed U.S. Psychiatrists are Receptive to Novel Treatments for CIAS, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 30, 2014 /PRNewswire/ -- Decision Resources Group finds that Bristol-Myers Squibb/Otsuka's Abilify is the branded agent with the highest patient share in schizophrenia, according to U.S. psychiatrists surveyed. Abilify is also one of the most preferred branded antipsychotics relative to other branded antipsychotics, according to surveyed managed...

2014-10-21 12:32:28

Ameritox's Ingenuity Health introduces method to help assess medication adherence in patients prescribed Risperdal® BALTIMORE, Oct. 21, 2014 /PRNewswire/ -- Ameritox(SM), the nation's leader in medication monitoring solutions, today launched a method to help assess medication adherence in behavioral health patients prescribed the antipsychotic drug risperidone (tradename, Risperdal(®)). This new method marks a critical step toward establishing a comprehensive reference database for...

aspirin for schizophrenia
2014-10-21 03:00:37

Provided by The European College of Neuropsychopharmacology A new study shows that some anti-inflammatory medicines, such as aspirin, estrogen, and Fluimucil, can improve the efficacy of existing schizophrenia treatments. This work is being presented at the European College of Neuropsychopharmacology conference in Berlin. For some time, doctors have believed that helping the immune system may benefit the treatment of schizophrenia, but until now there has been no conclusive evidence...

2014-10-21 08:33:06

-- Enrollment in Huntington's Trial Suspended Pending Further Assessment of Preclinical Data -- SEATTLE, Oct. 21, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today provided an update on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and Huntington's disease. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition. Omeros has...

2014-10-20 16:27:23

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854. The design of the Kinect 3 Study is a randomized, parallel-group, double-blind, placebo-controlled trial of approximately 240 subjects with moderate to severe tardive dyskinesia and an underlying diagnosis of mood disorder, schizophrenia or...

2014-10-17 23:04:35

Assurex Health and CAMH have been awarded a $6 Million Grant from Genome Canada to study the benefits of genetic testing to guide mental health medication decisions; schizophrenia patients are included for the first time in a study of this type. Mason, OH (PRWEB) October 17, 2014 Assurex Health and Canada’s Centre for Addiction and Mental Health (CAMH) today announced they have received a $6 million grant from Genome Canada, an agency of the Canadian government, to study the benefits of...

2014-10-15 12:31:56

NEW YORK, Oct. 15, 2014 /PRNewswire/ -- As Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to mount in U.S. courts, a hearing recently held in Vermont is raising serious questions about the adherence to pediatric dosing guidelines by doctors who prescribe antipsychotic drugs like Risperdal to children, Bernstein Liebhard LLP reports. According to Dr. David C. Rettew, Director of the Pediatric Psychiatry Clinic at University of Vermont's College of Medicine, a...

2014-10-10 23:03:37

With an estimated one in four adults or 26.2% of the population suffering from a diagnosable mental disorder in a given year, it’s time to erase the societal stigmas that have been placed on mental illness. As part of Mental Illness Week, Dr. Prakash Masand, a psychiatrist who is a former consulting professor of psychiatry and behavioral sciences at Duke University and the founder and CEO of Global Medical Education, says the only way to erase these societal stigmas is to understand...

schizophrenia
2014-10-09 09:08:11

Rayshell Clapper for redOrbit.com - Your Universe Online Most people have been affected by mental illness either personally or through friends, family and loved ones. The National Alliance on Mental Illness estimates that one in four American adults suffer from mental illness a year. Of those, about one in 17 live with a serious mental illness such as schizophrenia, major depression or bipolar disorder. All mental illnesses are dangerous and can be debilitating, which is why awareness...

2014-10-02 12:32:05

ARLINGTON, Va., Oct. 2, 2014 /PRNewswire-USNewswire/ -- Mental Illness Awareness Week (MIAW) is Oct. 5-11. What do you have planned? http://photos.prnewswire.com/prnvar/20100216/NAMILOGO MIAW is a time for education about mental illness such as depression, bipolar disorder, schizophrenia and other medical conditions that affect a person's thinking, feelings moods, ability to relate to others and daily functioning. MIAW includes National Depression Screening Day (Oct. 9.) and World Mental...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related